找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Clinical Pharmacology: Current Topics and Case Studies; Markus Müller (Professor and Head of Department) Book 20101st edition Springer-Ver

[復(fù)制鏈接]
樓主: monster
11#
發(fā)表于 2025-3-23 12:57:21 | 只看該作者
12#
發(fā)表于 2025-3-23 15:45:35 | 只看該作者
Current concepts of pharmacogenetics, pharmacogenomics, and the “druggable” genomelity can be translated into clinical practice. According to the current intriguing concepts of pharmacogenetics and pharmacogenomics, genetic information of individuals will be used to avoid “trial and error” scenarios during medication. Based on evidence from genomic testing, medicine is expected t
13#
發(fā)表于 2025-3-23 20:56:23 | 只看該作者
Biomarkerstifying biological markers as indicators for an underlying disease is an elementary concept in medicine. Since the beginning of the medical skill of healing, signs and symptoms have been interpreted by medical doctors and guided diagnosis and treatment of their patients. With the emergence of the bi
14#
發(fā)表于 2025-3-24 01:00:03 | 只看該作者
15#
發(fā)表于 2025-3-24 06:24:44 | 只看該作者
16#
發(fā)表于 2025-3-24 06:36:49 | 只看該作者
17#
發(fā)表于 2025-3-24 14:22:58 | 只看該作者
Safe Filler Injection Techniquesronic diseases and the determination of number of patients affected by a disease, the latter being a cornerstone of public healthcare and preventive medicine. Epidemiological research provides a methodological basis for determination of factors involved in disease progression and risk.
18#
發(fā)表于 2025-3-24 17:56:37 | 只看該作者
Epidemiology and bio statisticsronic diseases and the determination of number of patients affected by a disease, the latter being a cornerstone of public healthcare and preventive medicine. Epidemiological research provides a methodological basis for determination of factors involved in disease progression and risk.
19#
發(fā)表于 2025-3-24 22:53:03 | 只看該作者
Andrew M. Dearden,Michael D. Harrison, (b) clinically, by administering appropriate drug therapy to patients and (c) within a regulatory framework, to provide guidance on the risk/benefit ratio of drug candidates in drug development and drug reimbursement.
20#
發(fā)表于 2025-3-25 00:38:37 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-10 22:02
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
清水县| 荆州市| 西安市| 银川市| 周口市| 湟中县| 碌曲县| 嘉祥县| 洛南县| 瑞金市| 清河县| 炎陵县| 武功县| 新源县| 阜平县| 东城区| 梨树县| 宣化县| 德江县| 米易县| 鹤峰县| 金湖县| 涞水县| 南召县| 张家口市| 高淳县| 碌曲县| 广德县| 高雄县| 长阳| 衡水市| 兴业县| 探索| 海南省| 比如县| 乌兰浩特市| 山西省| 霸州市| 九台市| 崇义县| 松溪县|